Next Article in Journal
What Do We Know about the Role of miRNAs in Pediatric Sarcoma?
Next Article in Special Issue
Murine K2P5.1 Deficiency Has No Impact on Autoimmune Neuroinflammation due to Compensatory K2P3.1- and KV1.3-Dependent Mechanisms
Previous Article in Journal
NOS1AP O-GlcNAc Modification Involved in Neuron Apoptosis Induced by Excitotoxicity
Previous Article in Special Issue
Sleep Disorders Reduce Health-Related Quality of Life in Multiple Sclerosis (Nottingham Health Profile Data in Patients with Multiple Sclerosis)
 
 
Review

B Cells and Autoantibodies in Multiple Sclerosis

1
Department of Neurology, University Hospital Basel, Petersgraben 4 & Clinical Neuroimmunology, Hebelstrasse 20, 4031 Basel, Switzerland
2
Department of Biomedicine, University of Basel, Hebelstrasse 20, 4031 Basel, Switzerland
*
Author to whom correspondence should be addressed.
Academic Editors: Christoph Kleinschnitz and Sven Meuth
Int. J. Mol. Sci. 2015, 16(7), 16576-16592; https://doi.org/10.3390/ijms160716576
Received: 16 June 2015 / Revised: 15 July 2015 / Accepted: 15 July 2015 / Published: 21 July 2015
(This article belongs to the Special Issue Advances in Multiple Sclerosis)
While over the past decades T cells have been considered key players in the pathogenesis of multiple sclerosis (MS), it has only recently become evident that B cells have a major contributing role. Our understanding of the role of B cells has evolved substantially following the clinical success of B cell-targeting therapies and increasing experimental evidence for significant B cell involvement. Rather than mere antibody-producing cells, it is becoming clear that they are team players with the capacity to prime and regulate T cells, and function both as pro- and anti-inflammatory mediators. However, despite tremendous efforts, the target antigen(s) of B cells in MS have yet to be identified. The first part of this review summarizes the clinical evidence and results from animal studies pointing to the relevance of B cells in the pathogenesis of MS. The second part gives an overview of the currently known potential autoantigen targets. The third part recapitulates and critically appraises the currently available B cell-directed therapies. View Full-Text
Keywords: multiple sclerosis; neuromyelitis optica; B cells; autoantibodies; autoantigen; pathogenesis; therapy multiple sclerosis; neuromyelitis optica; B cells; autoantibodies; autoantigen; pathogenesis; therapy
MDPI and ACS Style

Pröbstel, A.-K.; Sanderson, N.S.R.; Derfuss, T. B Cells and Autoantibodies in Multiple Sclerosis. Int. J. Mol. Sci. 2015, 16, 16576-16592. https://doi.org/10.3390/ijms160716576

AMA Style

Pröbstel A-K, Sanderson NSR, Derfuss T. B Cells and Autoantibodies in Multiple Sclerosis. International Journal of Molecular Sciences. 2015; 16(7):16576-16592. https://doi.org/10.3390/ijms160716576

Chicago/Turabian Style

Pröbstel, Anne-Katrin, Nicholas S. R. Sanderson, and Tobias Derfuss. 2015. "B Cells and Autoantibodies in Multiple Sclerosis" International Journal of Molecular Sciences 16, no. 7: 16576-16592. https://doi.org/10.3390/ijms160716576

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop